Back to search
Eye Movement Disorder
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Eye Movement Disorder trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Eye Movement Disorder trials you may qualify forCardiac events can often result in debilitating and persistent psychological symptoms. A key question involves whether optimal treatment of cardiac-induced post…
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP). Eligible participants…
This clinical trial aims to evaluate whether individualized targeted repetitive transcranial magnetic stimulation (rTMS) can improve motor and non-motor symptom…
This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).
The goal of this observational and interventional study is to understand how therapeutic deep brain stimulation (DBS) affects attention, perception and cognitio…
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, with over 12 million patients expected globally by 2040…
Internuclear ophthalmoplegia is a symptom frequently associated with multiple sclerosis (MS), although other etiologies are possible. Some patients do not meet…
It is commonly admitted that social cognition impairment, like deficit in facial emotion recognition or misinterpretation of others' intentions (Theory of Mind)…
This pilot study aims to understand how eye movements change in people with vision loss from stroke after completing one of two types of training. The study wil…